An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)
Condition: Soft Tissue Sarcoma
MeSH terms: Sarcoma
Intervention: eribulin mesylate
Intervention description: Administration of eribulin mesylate at a dose of 1.4 mg/m^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 52.0
Sex: All
Minimum age: 20 Years
Healthy volunteers: No
Keywords: Soft Tissue Sarcoma

Summary:

      The purpose of the study is to evaluate the efficacy and safety of eribulin mesylate in
      subjects with soft tissue sarcoma who received at least one standard chemotherapy (an
      anthracycline or an ifosfamide monotherapy or a combination therapy).
    

Eligibility criteria:

        Inclusion Criteria

          -  Histologically or cytologically confirmed soft tissue sarcoma of high or intermediate
             grade

          -  Documented evidence of advanced or metastatic soft tissue sarcoma, not amenable to
             surgery or radiotherapy

          -  Within 6 months from the radiographic evidence of disease progression by RECIST
             criteria in the last chemotherapy regimen for advanced or metastatic soft tissue
             sarcoma

          -  Presence of measurable disease by Response Evaluation Criteria in Solid Tumors
             (RECIST) 1.1

          -  Subjects who received at least one standard chemotherapy for advanced soft tissue
             sarcoma (an anthracycline or an ifosfamide monotherapy, or a combination therapy)

          -  Subjects aged ≥ 20 years at the time of informed consent

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          -  Adequate organ function

          -  Voluntary agreement to provide written informed consent

        Exclusion Criteria

          -  A history of malignancies or recurrence within 5 years after the remission

          -  Significant cardiovascular impairment

          -  Any serious concomitant illness or infection requiring treatment.

          -  Hypersensitivity to either halichondrin B or halichondrin B chemical derivatives or
             both.

          -  Subjects who have previously participated in a study with eribulin (whether treated
             with eribulin or not).

          -  Any medical or other condition which, in the opinion of the principal investigator,
             will preclude participation in a clinical trial.

          -  Subjects who have received any anti-cancer therapy, including surgery, radiotherapy,
             immunotherapy, cytotoxic, hormonal, biological (including humanized antibodies) and
             targeted agents within 21 days, or any investigational agent within 30 days, prior to
             the first dose of study drug.

          -  Subjects who have not recovered from toxicities as a result of prior anti-cancer
             therapy to ≤ Grade 1, according to Common Terminology Criteria for Adverse Events
             (CTCAE), except for peripheral neuropathy of Grade 2 and alopecia.

          -  Subjects with known cerebral metastases with clinical symptoms or requiring treatment.

          -  Pre-existing peripheral neuropathy > CTCAE Grade 2.

          -  Female subjects must not be pregnant with a negative by the pregnancy test at
             Screening, or breastfeeding.

          -  Subjects participating in other clinical trials